Saturday 17 October 2026 Export DFTX’s income statement to Excel — free account

Definium Therapeutics, Inc.

In the quarter to June 2026, EPS fell 188.0%, free cash flow fell 78.3% and total debt fell 11.5%, each against the same quarter a year earlier.

32.10 2.16 −6.30%

Follow DFTX

Alert me

Market cap: $4.6B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 7.00

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	3	—	—	3	—	—	5	—	—	6	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 4,600.00

Revenue —

Net Income (353.78)

Free Cash Flow (167.95)

Net Debt (1,047.41)

Current Ratio 6.95

Debt/Equity 0.04

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.87

Past 5Y EPS Growth —

This Y EPS Growth (54.69%)

Next Y EPS Growth 35.76%

Next Y revenue growth —

Next 5Y EPS Growth 25.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 53.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	100	274	412	1,084
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	104	282	419	1,092

	2023	2024	2025	Q'26
Payables	4	2	5	7
ST’ Debt	—	—	—	—
Other	16	24	41	113
	32	39	67	157

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	34.37%	30.10%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(43)	(53)	—	—	—
’25	(29)	(30)	(30)	(43)	(132)
’24	(17)	(20)	(17)	(25)	(79)
’23	(13)	(14)	(17)	(21)	(64)
’22	(13)	(15)	(9)	(13)	(50)
’21	(10)	(11)	(17)	(8)	(46)
’20	(5)	(6)	(6)	(7)	(24)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(43)	(53)	—	—	—
’25	(29)	(30)	(30)	(43)	(132)
’24	(17)	(20)	(17)	(25)	(79)
’23	(13)	(14)	(17)	(21)	(64)
’22	(13)	(15)	(9)	(13)	(50)
’21	(10)	(11)	(17)	(8)	(46)
’20	(5)	(6)	(6)	(7)	(24)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.71)	(1.44)	—	—	—
’25	(0.27)	(0.50)	(0.78)	(0.50)	(2.06)
’24	(1.14)	(0.08)	(0.17)	(0.41)	(1.54)
’23	(0.65)	(0.76)	(0.45)	(0.59)	(2.44)
’22	(0.60)	(0.60)	(0.56)	(0.02)	(1.84)
’21	(0.60)	(1.35)	(0.61)	(0.60)	(3.45)
’20	(0.52)	(0.30)	(0.45)	(0.58)	(1.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.38	3.59	0.32	0.02	0.75	20.27	2.12	2.20	3.49	4.70	Analyst estimates 2026–2028 Powerpack
	High	8.24	19.35	6.21	1.95	76.05	86.55	23.10	5.01	12.22	14.43
People
People	Employees	—	—	—	—	—	41	48	57	74	106
	Revenue/emp, $m	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	0	(1)	(1)	(11)	(34)	(94)	(57)	(96)	(109)	(184)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	0	0	(1)	(11)	(34)	(93)	(57)	(96)	(109)	(184)
	Depreciation	—	0	0	0	0	3	3	3	1	(2)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(0.09)	(3.88)	(2.02)	(1.56)	(1.50)	(3.45)	(1.84)	(2.44)	(1.54)	(2.06)
	Cash flow	(0.02)	(2.11)	(1.70)	(0.47)	(1.33)	(1.67)	(1.62)	(1.64)	(1.12)	(1.47)
	Capex	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(0.02)	(2.11)	(1.70)	(0.47)	(1.33)	(1.67)	(1.62)	(1.64)	(1.12)	(1.47)
	Book value	0.08	12.49	8.29	0.00	4.27	5.54	4.89	2.00	3.43	3.72
	Shares, m	1	0	0	7	18	27	31	39	70	89
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	(3)	(24)	(46)	(50)	(64)	(79)	(132)
	Capex	0	(2)	(1)	0	—	—	—	—	—	—
	Free cash flow	0	(1)	(1)	(3)	(24)	(46)	(50)	(64)	(79)	(132)
Balance, $m
Balance, $m	Working capital	0	1	0	2	79	127	128	72	243	353
	Total debt	—	0	—	—	—	—	0	14	22	41
	Net debt	0	(1)	0	0	(80)	(134)	(142)	(86)	(252)	(371)
	Shareholders’ equity	0	3	3	—	76	152	151	78	241	332
Returns, %
Returns, %	ROA	(7.90)	(1,306.54)	(45.91)	(823.70)	(80.69)	(75.79)	(34.01)	(65.01)	(50.94)	(49.52)
	ROIC	0.00	0.00	0.00	0.00	0.00	(323.63)	(472.44)	0.00	0.00	0.00
	ROE	(8.20)	(60.35)	(21.94)	(455.48)	(87.05)	(81.78)	(37.54)	(83.59)	(68.01)	(64.06)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%	Compare
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%
DNTH Dianthus Therapeutics, Inc.	$4.2B	— (loss-making)	— (loss-making)	+294.30% (above 0%: growing)	n/m	−105.37% (below 0%: shrinking)	100.00%	(8,079.11%)	Compare
EWTX Edgewise Therapeutics, Inc.	$4.2B	— (loss-making)	—	—	n/m	−30.24% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+197.93%	—	−10.68%	47.24%	0.00%

All 614 Biotechnology stocks →

Definium Therapeutics, Inc. (DFTX) key facts

Definium Therapeutics, Inc. (DFTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DFTX traded at $32.10, a market capitalization of $4.6 billion.
Return on equity was −64.1% and debt-to-equity 0.04.

Source: company filings (standardised) and stockrow calculations.